UPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)
Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.
According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades Legacy Reserves (LGCY) to Hold
- Volatility and Volume movement
- Graphic Packaging (GPK) PT, Estimates Trimmed at Jefferies Post Q3
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!